Format

Send to

Choose Destination
J Nucl Med Technol. 2016 Dec;44(4):217-222. Epub 2016 Sep 15.

The Role of 18F-Sodium Fluoride PET/CT Bone Scans in the Diagnosis of Metastatic Bone Disease from Breast and Prostate Cancer.

Author information

1
Queensland X-Ray, Cairns Private Hospital, Cairns, Australia rkul22@gmail.com.
2
Department of Nuclear Medicine, Royal Liverpool Hospital, Liverpool, United Kingdom; and.
3
School of Health Sciences, University of Salford, Salford, United Kingdom.

Abstract

We describe the role of 18F-sodium fluoride (18F-NaF) PET/CT bone scanning in the staging of breast and prostate cancer. 18F-NaF PET was initially utilized as a bone scanning agent in the 1960s and early 1970s, however, its use was restricted by the then-available γ-cameras. The advent of hybrid PET/CT cameras in the late 1990s has shown a resurgence of interest in its use and role. After a brief introduction, this paper describes the radiopharmaceutical properties, dosimetry, pharmacokinetics, and mechanism of uptake of 18F-NaF. The performance of 18F-NaF PET/CT is then compared with that of conventional bone scintigraphy using current evidence from the literature. Strengths and weaknesses of 18F-NaF PET/CT imaging are highlighted. Clinical examples of improved accuracy of diagnosis and impact on patient management are illustrated. Limitations of 18F-NaF PET/CT imaging are outlined.

KEYWORDS:

18F-sodium fluoride PET/CT; 99mTc-MDP; bone metastases; bone scintigraphy; breast cancer; prostate cancer

PMID:
27634981
DOI:
10.2967/jnmt.116.176859
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center